New drug trial targets rare kidney disease at genetic root
NCT ID NCT05448755
First seen Mar 31, 2026 · Last updated May 13, 2026 · Updated 5 times
Summary
This early study tested a drug called ELX-02 in 3 people with Alport syndrome, a genetic kidney disease. The goal was to see if the drug is safe and if it can reduce protein in the urine, a sign of kidney damage. Participants received daily injections for 8 weeks and were followed for 3 months after.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPORT SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Great Ormond Street Hospital
London, WC1N 3JH, United Kingdom
-
Monash Medical Center
Clayton, Victoria, 3168, Australia
-
Royal Children's Hospital
Parkville, Victoria, 3051, Australia
-
Royal Free Hospital
London, NW3 2QG, United Kingdom
Conditions
Explore the condition pages connected to this study.